Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 13;175(7):1719.
doi: 10.1016/j.cell.2018.11.049.

CGRP Antibodies as Prophylaxis in Migraine

Affiliations
Free article
Review

CGRP Antibodies as Prophylaxis in Migraine

Lars Edvinsson. Cell. .
Free article

Abstract

Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.

Similar articles

See all similar articles

Cited by 3 articles

MeSH terms

Feedback